> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS Resolves Abraxane Drug Shortage
- URL: https://www.fdaweb.com/bms-resolves-abraxane-drug-shortage/
- Published: 2022-03-25T12:00:00.000Z
- Updated: 2026-09-14T17:38:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151454

Bristol-Myers Squibb (BMS) says it has resolved manufacturing constraints that led to “global supply challenges” for Abraxane (paciltaxel protein bound particles for injectable suspension). In a [just-posted letter](https://www.fda.gov/media/156959/download?ref=fdaweb.com) on steps it took to resolve the drug shortage, BMS says the drug product manufacturing site has now returned to normal operations.

According to its chronology of events, BMS says that in 4/2021 there was an unanticipated event at the primary drug product manufacturing site for Abraxane. “Given the planned mitigation strategies, which included obtaining additional supplies from an alternate, ex-U.S. drug product manufacturing site, it was concluded that there was low risk of a meaningful disruption of supply of Abraxane in the United States,” the company explains. “After further evaluation, BMS recognized the potential for a supply disruption and a notification was sent to \[FDA’s Drug Shortage Staff\] on 6/18/2021.

Subsequently, on 9/3/2021 the company told DSS that delays in receipt of packaging components at the alternate site resulted in additional constraint for supply. On 9/13 BMS issued a letter to healthcare providers about the supply disruption.

BMS said inventory levels are now expected to be at or above adequate coverage levels through the second quarter for the U.S. market.